The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus
Clin Gastroenterol Hepatol. 2022 Mar 8;S1542-3565(22)00214-2.doi: 10.1016/j.cgh.2022.02.056. Online ahead of print.
Jennifer R Kramer1, Peter A Richardson1, Hyunseok Kim2, Yao-Chun Hsu2, Fasiha Kanwal3, Hashem B El-Serag4
Author information
Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Fu-Jen Catholic University Hospital/E-DA Hospital, Kaohsiung, Taiwan.
Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; Section of Gastroenterology and Hepatology, Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; Section of Gastroenterology and Hepatology, Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas. Electronic address: hasheme@bcm.edu.
Abstract
The comparative effectiveness of tenofovir (TDF) vs entecavir (ETV) in reducing the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) remains unclear. Data from a retrospective Korean cohort study published by Choi et al1 initially suggested a lower-than-expected incidence of HCC in patients on long-term TDF. However, additional studies from Korea did not show a statistically significant difference in HCC incidence rate between TDF and ETV groups,2,3 and subsequent studies reported mixed results ranging from no association or a slight advantage for TDF.4 Most of these studies examined Asian patients from Korea, Taiwan, and China.